ArticleMedical care2026
Continuity of Medications for Opioid Use Disorder in States With and Without Medicaid Prescription Cap Policies.
Article in Medical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMedicaid prescription cap policies persist in 12 states; however, it is unclear how they affect the quality of opioid use disorder (OUD) treatment.
objectivesTo examine the association between cap policies and the continuity in receipt of medication for OUD (MOUD) treatment in Medicaid.
methodsUsing 2016-2021 T-MSIS Analytical Files data from 37 states, we identified nondual adult (18-64 y) Medicaid enrollees diagnosed with OUD who received MOUD. The exposure was the state's Medicaid prescription cap policy status. The main outcome was a binary variable for MOUD continuity, overall and by type, defined as no treatment gap exceeding 7 consecutive days during a 180-day observation period. We estimated risk ratios for MOUD continuity using modified Poisson regression models, adjusting for individual and state-level covariates to test associations.
resultsNearly half the sample was female, and the mean age was 37 years. MOUD continuity ranged from 40.7% to 44.3% in states without cap policies and 37.5%-39.6% in cap states. Compared with enrollees in noncap states, those in cap states had a 12% higher likelihood of experiencing at least 1 MOUD treatment gap [risk ratio (RR)=1.12; 95% CI: 1.12-1.13]. These findings were consistent for buprenorphine and methadone. Factors associated with overall MOUD discontinuity included younger age, male sex, living in nonmetropolitan areas, and having 3 or more comorbidities.
conclusionsPrescription caps were associated with reduced continuity of MOUD, overall and for buprenorphine and methadone, suggesting that revising or removing these policies could improve OUD quality metrics in Medicaid.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.